Ayala Pharmaceuticals, Inc.
ADXS · OTC
12/31/2023 | 12/31/2022 | 1/31/2022 | 1/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.01 | 0.01 | 0.03 |
| FCF Yield | -737.87% | -709.55% | -88.61% | -52.88% |
| EV / EBITDA | -0.21 | 1.46 | 1.26 | -0.97 |
| Quality | ||||
| ROIC | 405.38% | -68.07% | -48.26% | -73.07% |
| Gross Margin | 0.00% | -25.60% | -14.44% | -407.91% |
| Cash Conversion Ratio | 0.61 | 1.06 | 0.86 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | -84.11% | -0.40% | 11.55% | -65.31% |
| Free Cash Flow Growth | -90.41% | 2.60% | 29.92% | -39.36% |
| Safety | ||||
| Net Debt / EBITDA | -0.10 | 1.60 | 2.22 | 0.79 |
| Interest Coverage | -2.30 | 0.00 | -72.25 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -1.34 | -5.44 | 0.96 |
| Cash Conversion Cycle | -170,595.38 | 44.06 | -212.29 | 749.90 |